Gary Larson

1.6k citations

60 papers · 1.3k indexed · h-index 21

Impact in

Radiation top 5%
- Advanced Radiotherapy Techniques
Hepatology top 5%
- Hepatitis C virus research

Papers in ⓘ

Pulmonary and Respiratory Medicine 26
- Radiation Therapy and Dosimetry 17
- Prostate Cancer Diagnosis and Treatment 13
- Prostate Cancer Treatment and Research 10
Radiation 16
- Advanced Radiotherapy Techniques 16

Co-authors: Jim Zhen Wu (12 shared papers)Zhi Hong (7 shared papers)Shunqi Yan (6 shared papers)Carlos Vargas (33 shared papers)T.C. Appleby (5 shared papers)Robert Hamatake (5 shared papers)William F. Hartsell (27 shared papers)Nanhua Yao (5 shared papers)
Journals: International Journal of Radiation Oncology*Biology*Physics (14 papers)Bioorganic & Medicinal Chemistry Letters (6 papers)Acta Oncologica (5 papers)Molecular Cancer Therapeutics (3 papers)Advances in Radiation Oncology (3 papers)
Partner nations: United States Norway Italy

In The Last Decade

Gary Larson

58 papers receiving 1.2k citations

Peers

Countries citing papers authored by Gary Larson

Since Specialization

Citations

This map shows the geographic impact of Gary Larson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Larson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Larson more than expected).

Fields of papers citing papers by Gary Larson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Larson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Larson. The network helps show where Gary Larson may publish in the future.

Co-authors

The 25 scholars most cited alongside Gary Larson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gary Larson Line = papers co-authored together Gary Larson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer Cancer Research ·Cory Iverson, Gary Larson, Chon Lai, Li‐Tain Yeh, Claudia Dadson, Paul Weingarten, T.C. Appleby, Todd Vo, Andreas Maderna, Jean‐Michel Vernier, Robert Hamatake, Jeffrey N. Miner, Barry Quart	2009	153
2	Structure–activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors Bioorganic & Medicinal Chemistry Letters ·Frank Rong, Suetying Chow, Shunqi Yan, Gary Larson, Zhi Hong, Jim Zhen Wu	2007	99
3	2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules Molecular Cancer Therapeutics ·Kathy Kamath, Tatiana Okouneva, Gary Larson, Dulal Panda, Leslie Wilson, Mary Ann Jordan	2006	78
4	Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2 Molecular Cancer Therapeutics ·Luigi Carlessi, Giacomo Buscemi, Gary Larson, Zhi Hong, Jim Zhen Wu, Domenico Delia	2007	74
5	Selection of 3′-Template Bases and Initiating Nucleotides by Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase Journal of Virology ·Jae Hoon Shim, Gary Larson, Jim Zhen Wu, Zhi Hong	2002	51
6	Parallel synthesis of 5-cyano-6-aryl-2-thiouracil derivatives as inhibitors for hepatitis C viral NS5B RNA-dependent RNA polymerase Bioorganic Chemistry ·Yili Ding, Jean‐Luc Girardet, Kenneth L. Smith, Gary Larson, Brett J. Prigaro, Jim Zhen Wu, Nanhua Yao	2005	49
7	Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure Bioorganic & Medicinal Chemistry Letters ·Shunqi Yan, Gary Larson, Jim Zhen Wu, T.C. Appleby, Yili Ding, Robert Hamatake, Zhi Hong, Nanhua Yao	2006	46
8	Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors Bioorganic & Medicinal Chemistry Letters ·Shunqi Yan, T.C. Appleby, Gary Larson, Jim Zhen Wu, Robert Hamatake, Zhi Hong, Nanhua Yao	2006	46
9	Phosphorylation of Ribavirin and Viramidine by Adenosine Kinase and Cytosolic 5′-Nucleotidase II: Implications for Ribavirin Metabolism in Erythrocytes Antimicrobial Agents and Chemotherapy ·Jim Zhen Wu, Gary Larson, Heli Walker, Jae Hoon Shim, Zhi Hong	2005	44
10	Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: Convergence of structure-based drug design and X-ray crystallographic study Bioorganic & Medicinal Chemistry Letters ·Shunqi Yan, T.C. Appleby, Gary Larson, Jim Zhen Wu, Robert Hamatake, Zhi Hong, Nanhua Yao	2007	44
11	Interaction of the Antitumor Compound Cryptophycin-52 with Tubulin Biochemistry ·Dulal Panda, Vidya Ananthnarayan, Gary Larson, Chuan Shih, Mary Ann Jordan, Leslie Wilson	2000	38
12	Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies Practical Radiation Oncology ·Shahed N. Badiyan, Michael S. Rutenberg, Bradford S. Hoppe, Pranshu Mohindra, Gary Larson, William F. Hartsell, Henry Tsai, Jing Zeng, Ramesh Rengan, Erica Glass, Sanford Katz, Carlos Vargas, Steven J. Feigenberg, Charles B. Simone	2019	33
13	Identification of novel, selective and potent Chk2 inhibitors Bioorganic & Medicinal Chemistry Letters ·Gary Larson, Shunqi Yan, Huanming Chen, Frank Rong, Zhi Hong, Jim Zhen Wu	2006	31
14	A Multi-Institutional Experience of Proton Beam Therapy for Sinonasal Tumors Advances in Radiation Oncology ·Nathan Y. Yu, Mauricio E. Gamez, William F. Hartsell, Henry Tsai, George E. Laramore, Gary Larson, Charles B. Simone, Carl J. Rossi, Sanford Katz, Matthew Buras, Michael A. Golafshar, Carlos Vargas, Samir H. Patel	2019	30
15	Proton beam therapy reirradiation for breast cancer: Multi‐institutional prospective PCG registry analysis The Breast Journal ·C.S. Thorpe, Joshua R. Niska, Marlene Girardo, Heidi Kosiorek, L.A. McGee, William F. Hartsell, Gary Larson, Henry Tsai, Carl J. Rossi, L Rosen, Carlos Vargas	2019	30
16	Parallel synthesis of pteridine derivatives as potent inhibitors for hepatitis C virus NS5B RNA-dependent RNA polymerase Bioorganic & Medicinal Chemistry Letters ·Yili Ding, Jean‐Luc Girardet, Kenneth L. Smith, Gary Larson, Brett J. Prigaro, Vicky C. H. Lai, Weidong Zhong, Jim Zhen Wu	2004	28
17	Clinical Outcomes in Patients with Recurrent Glioblastoma Treated with Proton Beam Therapy Reirradiation: Analysis of the Multi-Institutional Proton Collaborative Group Registry Advances in Radiation Oncology ·Ali Saeed, Rahul Khairnar, Ankur Sharma, Gary Larson, Henry Tsai, Chiachien J. Wang, Lia M. Halasz, Prakash Chinnaiyan, Carlos Vargas, Mark V. Mishra	2020	27
18	Dosimetric study of uniform scanning proton therapy planning for prostate cancer patients with a metal hip prosthesis, and comparison with volumetric‐modulated arc therapy Journal of Applied Clinical Medical Physics ·Suresh Rana, ChihYao Cheng, Yuanshui Zheng, Wen C. Hsi, O. Zeidan, Niek Schreuder, Carlos Vargas, Gary Larson	2014	24
19	Minimal acute toxicity from proton beam therapy for major salivary gland cancer Acta Oncologica ·Michael D. Chuong, John Michael Bryant, William F. Hartsell, Gary Larson, Shahed N. Badiyan, George E. Laramore, Sanford Katz, Henry Tsai, Carlos Vargas	2019	24
20	Hypofractionated Versus Standard Fractionated Proton-beam Therapy for Low-risk Prostate Cancer American Journal of Clinical Oncology ·Carlos Vargas, William F. Hartsell, Megan Dunn, Sameer R. Keole, Lucius Doh, Elaine Eisenbeisz, Gary Larson	2015	24

About Gary Larson

Gary Larson is a scholar working on Pulmonary and Respiratory Medicine, Radiation, Oncology, Molecular Biology and Hepatology, having authored 60 papers that have together received 1.3k indexed citations. Recurring topics across this work include Radiation Therapy and Dosimetry (17 papers), Advanced Radiotherapy Techniques (16 papers), Prostate Cancer Diagnosis and Treatment (13 papers), Prostate Cancer Treatment and Research (10 papers), Hepatitis C virus research (9 papers), HIV/AIDS drug development and treatment (7 papers), Breast Cancer Treatment Studies (6 papers) and Biochemical and Molecular Research (5 papers). The work is most often cited by research in Radiation (226 citations), Hepatology (168 citations), Pulmonary and Respiratory Medicine (350 citations), Organic Chemistry (280 citations) and Oncology (220 citations). Gary Larson has collaborated with scholars based in United States, Norway and Italy. Frequent co-authors include Jim Zhen Wu, Zhi Hong, Shunqi Yan, Carlos Vargas, T.C. Appleby, Robert Hamatake, William F. Hartsell, Nanhua Yao, Henry Tsai and Jae Hoon Shim. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Bioorganic & Medicinal Chemistry Letters, Acta Oncologica, Molecular Cancer Therapeutics and Advances in Radiation Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact